1Anuradha S, Singh NP, Agarwal SK. Total dose infusion iron dextran therapy in predialysis chronic renal failure patients. Ren Fail,2002,24:307- 313.
2Sloand JA, Shekky MA, Erenstone AL, et al. Safety and efficacy af total dose iron dextran administration in patients on home renal replacement therapies. Perit Dial Int, 1998,18:522-527.
2Sav T,Tokgoz B, Sipahioglu MH, et al. allergic potencies of the iron sucrose dextran? Ren Fail ,2007,29:423-426.
3Is there a difference between the and low molecular weight iron Li H, Wang SX. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif,2008,26 : 151-156.
4Wish .IB. Intravenous iron: not just for hemodialysis patients anymore. Perit Dial Int,2008 ,28:126-129.
5Madore F, White CT, Foley RN, et al. Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int Suppl,2008, 110:S7-Sl1:.
6Devita MV, Frumkin D, Mittal S, et al. Targeting higher ferritin concentra- tions with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Neph rol, 2003,60 : 335 -340.
7Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol, 2006,26:261-268.
8Fishbane S, Singh AK. Iron deficiency in non-dialysis chronic kidney disease. Kidney Int,2009 ,75 :752-754.
9Munoz M, Breymann C, Garcia-erce JA, et al. Efficacy and safety of intra- venous iron therapy as an alternative/adjunct to allogeneic blood transfu- sion. Vox Sang,2008,94 : 172 -183.
10Horl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephro1,2007 ,18 :382-393.
